GenScript [HKEX:1548]
Connecting Gene Therapy from Discovery to Clinical Supply
Ray Chen, President
Top Gene Therapy Solutions in APAC 2026
Gene therapy solutions help life sciences organizations develop and deliver treatments that address disease at the genetic level. With a focus on vector quality, therapeutic precision, regulatory readiness and patient safety, they support advanced care pathways and stronger medical innovation.
Solutions
![GenScript [HKEX:1548]: Connecting Gene Therapy from Discovery to Clinical Supply](https://www.lifesciencesreviewapac.com/newstransfer/upload/4142-uk0sp.jpg "GenScript [HKEX:1548]: Connecting Gene Therapy from Discovery to Clinical Supply")
A promising gene therapy can lose momentum each time the material behind it has to be rebuilt for the next development stage. A guide RNA that works during discovery may later need a higher-grade counterpart produced under tighter controls. A plasmid created for early vector work can eventually become part of a clinical manufacturing process. At each handoff, new requirements appear and with them comes the risk that the material used later will no longer perform exactly as the earlier material did.
State of Industry
Precision Medicine in APAC: The Role of Gene Therapy Solutions
Gene therapy solutions are transforming the healthcare landscape by addressing diseases at their genetic source rather than focusing solely on symptom management. By modifying, replacing, or repairing defective genes, these therapies offer new possibilities for treating inherited disorders, cancer, and other complex medical conditions.
Leadership Perspective
CSL Behring
Chemistry, Manufacturing, and Controls (CMC) Strategies to Control Cost of Goods (COGS) for Gene Therapy Products
Yan Zhi, Ph.D. Director, Sustain and Improve (S&I) Lead
Yan Zhi is Director, Sustain and Improve (S&I) Lead at CSL Behring. She leads CMC strategy for global regulatory submissions and manages tech transfers for AAV-based gene therapies. With broad experience in development, manufacturing, and commercial launch, she brings deep expertise in viral vectors and a strong track record of advancing gene therapy products from lab to market.
Gene Therapy Solutions in APAC Info
Q1
What Do Top Gene Therapy Solutions in APAC Include?
Top Gene Therapy Solutions in APAC cover the development tools and services used to move a gene therapy program from early research toward clinical use. These can include gene synthesis, sequencing, gene editing, plasmid development, viral-vector work, non-viral delivery, analytical support and manufacturing. The scope can vary by provider, but the central goal is to connect biological design with reliable materials and development processes across different stages.
Q2
Which Provider Was Recognized for Top Gene Therapy Solutions in APAC in 2026?
Life Science Review APAC recognized GenScript as a Top Gene Therapy Solutions provider in APAC for 2026. The recognition reflects its connected approach to gene-therapy development, spanning target discovery, payload and vector development, phase-appropriate materials and clinical manufacturing support.
Q3
Why Is Demand for Gene Therapy Solutions in APAC Growing?
Demand for Top Gene Therapy Solutions in APAC is shaped by the expansion of gene-editing research, advanced delivery methods and clinical development across the region. Developers need access to specialized research materials and manufacturing capabilities as programs move from laboratory work toward regulatory and clinical stages. Regional infrastructure can also make technical resources and production capacity more accessible to developers working across APAC markets.
Q4
What Should Organizations Evaluate When Choosing Gene Therapy Solutions in APAC?
When assessing Top Gene Therapy Solutions in APAC, organizations should look beyond individual products or services. They can consider whether a provider supports the relevant development stage, delivery approach and material grade, as well as how easily a program can progress into later manufacturing. Technical consistency, quality controls, regulatory readiness, development timelines and the ability to maintain continuity between research and clinical materials can also affect program risk and planning.
Q5
How Does Technology Shape Gene Therapy Solutions in APAC?
Technology influences Top Gene Therapy Solutions in APAC through advances in gene editing, delivery systems and manufacturing processes. Viral approaches such as AAV and lentiviral systems may be used alongside non-viral technologies such as synthetic guide RNA and mRNA-based delivery. The ability to design payloads and delivery systems together, improve material control and support transitions toward CMC and GMP manufacturing can help development teams manage the technical demands of later stages.
Q6
Why Was GenScript Recognized for Gene Therapy Solutions in APAC in 2026?
The fact that GenScript has been recognised by Life Science Review APAC is based on a number of documented capabilities. Its platform links together gene synthesis, sequencing, engineered cell models and CRISPR-based screening with the development of payloads and vectors. It also offers support for AAV and lentiviral systems, synthetic guide RNAs, Cas nucleases and mRNA-LNP technologies. In later stages of development, its ProBio subsidiary provides CMC and GMP support for plasmid and viral-vector programmes, thus establishing a route to clinical supply while at the same time keeping the earlier development work linked to the later manufacturing requirements. This places GenScript in the category of Top Gene Therapy Solutions in APAC.
